Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
AbbVie (ABBV.US) signs a deal worth up to $2.54 billions with Germany's Disco Pharmaceuticals to strengthen next-generation bispecific antibody cancer therapies

AbbVie (ABBV.US) signs a deal worth up to $2.54 billions with Germany's Disco Pharmaceuticals to strengthen next-generation bispecific antibody cancer therapies

智通财经智通财经2026/11/19 08:45
Show original
According to reports from Zhitong Finance APP, German private biotechnology company Disco Pharmaceuticals stated on Thursday that AbbVie (ABBV.US) has agreed to pay up to $2.54 billion to jointly develop cancer therapies with Disco. This marks the pharmaceutical company's early move in next-generation bispecific antibody therapies.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!